Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

113.50 

-0.31 -0.3%

as of May 22 '17 12:57

52 Week Range:

87.50 139.79


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; CorMatrix portfolio of vascular, cardiac, and pericardial tissue repair products; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Carnexiv that is used as replacement therapy for oral carbamazepine formulations; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer. The company’s partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others. Its internal development program comprise products for the treatment of Type 2 diabetes mellitus, oncology, allergy, anti-coagulant, depression, sun damage, blood disorders, and diabetes. The company is also involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated has alliances, licenses, and other business relationships with various pharmaceutical companies, including Novartis AG; Amgen, Inc.; Merck & Co., Inc.; Pfizer Inc.; Celgene; Gilead Sciences; Janssen Biotech, Inc.; Baxter International, Inc.; and Eli Lilly and Company. The company was founded in 1987 and is headquartered in San Diego, California.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16
Equity (BVPS) -15.15
1.85
-0.66
0.19
-0.25
0.12
1.31
2.19
2.27
14.65
16.18
growth rate 100.0% -100.0% 100.0% -100.0% 100.0% 991.7% 67.2% 3.7% 545.4% 10.4%
Earnings BIT -174.27
-53.46
-97.52
-9.87
-15.40
-2.95
-3.87
9.21
16.16
47.13
20.14
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 75.5% 191.6% -57.3%
Avg.PE -15.70
-20.90
-3.20
-34.50
-15.00
22.99
-118.50
121.95
98.34
8.25
287.62
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% -100.0% 100.0% -19.4% -91.6% 3,386.3%
ROA -9.91
112.83
-56.92
-1.24
-9.54
10.28
-0.47
10.93
6.63
64.98
-0.29
growth rate 100.0% -100.0% 0.0% 0.0% 100.0% -100.0% 100.0% -39.3% 880.1% -100.0%
ROE -142.60
997.71
-1,046.50
-69.00
-365.80
536.00
-3.00
30.01
31.67
155.61
-0.51
growth rate 100.0% -100.0% 0.0% 0.0% 100.0% -100.0% 100.0% 5.5% 391.4% -100.0%
ROIC 561.34
-803.41
35.22
3.76
20.13
8.45
70.21
-0.31
growth rate -100.0% 100.0% -89.3% 435.4% -58.0% 730.9% -100.0%
Cur. Ratio 1.38
2.16
1.33
1.31
1.11
0.74
0.67
0.86
8.13
10.35
0.72
growth rate 56.5% -38.4% -1.5% -15.3% -33.3% -9.5% 28.4% 845.4% 27.3% -93.0%
Quick Ratio 1.07
1.85
1.31
1.22
1.08
0.67
0.60
0.78
7.94
10.17
0.70
growth rate 72.9% -29.2% -6.9% -11.5% -38.0% -10.5% 30.0% 918.0% 28.1% -93.1%
Leverage 11.92
5.95
37.88
14.15
3.94
2.11
9.80
1.75
1.76
growth rate -50.1% 152.3% -38.9% -72.2% -46.5% 364.5% -82.1% 0.6%
Balance Sheet Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16
Acct.Receivable 0.00
0.60
1.00
12.54
8.92
6.55
12.63
10.95
17.91
growth rate 66.7% 1,154.4% -28.9% -26.5% 92.9% -13.3% 63.5%
Acct.Payable 16.12
12.40
10.86
12.56
9.49
9.13
growth rate -23.1% -12.4% 15.7% -24.5% -3.8%
Cur.Assets 93.90
68.20
37.00
32.23
23.82
24.88
185.16
214.71
163.05
growth rate -27.4% -45.8% -12.9% -26.1% 4.4% 644.2% 16.0% -24.1%
Total Assets 171.40
141.80
75.60
120.58
104.26
104.71
258.03
503.06
601.59
growth rate -17.3% -46.7% 59.5% -13.5% 0.4% 146.4% 95.0% 19.6%
Cash 28.80
16.00
3.30
7.04
12.38
11.64
160.20
97.43
18.75
growth rate -44.4% -79.4% 113.4% 75.8% -6.0% 1,276.4% -39.2% -80.8%
Inventory 0.00
0.00
0.00
1.30
1.70
1.39
0.27
1.63
1.92
growth rate 30.4% -18.0% -80.7% 507.1% 17.8%
Cur.Liabilities 70.60
52.20
33.50
43.64
35.44
28.94
22.78
222.82
227.13
growth rate -26.1% -35.8% 30.3% -18.8% -18.3% -21.3% 878.2% 1.9%
Liabilities 181.80
138.10
80.40
104.05
77.78
55.10
231.71
226.15
230.73
growth rate -24.0% -41.8% 29.4% -25.3% -29.2% 320.5% -2.4% 2.0%
LT Debt 2.16
0.63
49.70
36.30
0.00
28.65
19.41
3.07
196.84
205.37
growth rate -71.0% 7,826.6% -27.0% -100.0% -32.3% -84.2% 6,309.7% 4.3%
Equity 39.70
41.46
1.98
3.70
3.50
8.19
26.49
49.61
26.32
237.28
341.29
growth rate 4.4% -95.2% 86.9% -5.4% 133.9% 223.6% 87.3% -47.0% 801.6% 43.8%
Common Shares 13.00
16.00
16.00
19.00
20.00
20.00
20.00
21.00
0.02
0.02
0.02
growth rate 23.1% 0.0% 18.8% 5.3% 0.0% 0.0% 5.0% -99.9% 0.0% 5.0%
Cash Flow Statement Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16
Capital Expenditures 1.78
0.44
0.40
0.40
0.70
0.08
0.60
0.38
0.01
0.09
1.85
growth rate -75.3% -9.1% 0.0% 75.0% -88.9% 662.8% -36.6% -98.4% 1,450.0% 1,889.3%
Cash Dividends 0.00
252.74
0.00
0.00
0.00
0.00
0.00
growth rate -100.0%
Cash From OA -138.52
-97.73
-20.63
-33.80
-27.07
-1.17
0.16
20.69
20.57
41.73
63.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 12,750.9% -0.6% 102.9% 51.0%
FCF per Share -3.44
-6.00
-1.33
-1.82
-1.38
-0.41
-0.02
0.34
1.03
1.58
1.61
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 202.9% 53.4% 1.9%
Sale Purchase of Stock 0.00
6.42
3.13
-51.76
8.36
2.51
growth rate 100.0% -51.3% -100.0% 100.0% -69.9%
FCF -140.00
-98.00
-21.00
-34.00
-27.00
-1.00
-0.40
17.00
20.00
38.00
43.00
growth rate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 17.7% 90.0% 13.2%
Income Statement Dec '06 Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16
Sales 3.98
12.89
27.30
38.90
23.50
30.04
31.39
48.97
64.54
71.91
108.97
growth rate 223.9% 111.8% 42.5% -39.6% 27.8% 4.5% 56.0% 31.8% 11.4% 51.5%
Op.Income -97.30
-10.00
-29.30
9.71
-2.67
8.83
19.63
27.33
43.89
growth rate 0.0% 0.0% 100.0% -100.0% 100.0% 122.2% 39.3% 60.6%
IBT -97.50
-9.90
-15.40
-3.56
-3.87
9.21
11.30
35.33
7.96
growth rate 0.0% 0.0% 0.0% 0.0% 100.0% 22.8% 212.6% -77.5%
Net Income -98.10
-1.90
-10.40
9.71
-2.67
8.83
12.02
229.82
-1.64
growth rate 0.0% 0.0% 100.0% -100.0% 100.0% 36.1% 1,811.4% -100.0%
EPS -2.34
17.22
-6.18
-0.10
-0.53
0.49
-0.03
0.55
0.56
10.83
-0.08
growth rate 100.0% -100.0% 0.0% 0.0% 100.0% -100.0% 100.0% 1.8% 1,833.9% -100.0%
Gross Profit 3.98
12.89
27.30
38.90
23.50
25.13
27.79
43.24
55.40
66.11
103.40
growth rate 223.9% 111.8% 42.5% -39.6% 6.9% 10.6% 55.6% 28.1% 19.3% 56.4%
R&D 30.80
39.90
22.10
10.29
10.79
9.27
9.75
11.01
21.22
growth rate 29.6% -44.6% -53.4% 4.9% -14.1% 5.1% 12.9% 92.8%

Quarterly Statements

Item Name Mar '16 Jun '16 Sep '16 Dec '16 Mar '17
Earnings BIT 12.58
-7.00
4.33
10.24
9.13
growth rate -100.0% 100.0% 136.5% -10.8%
Balance Sheet Mar '16 Jun '16 Sep '16 Dec '16 Mar '17
Acct.Receivable 16.55
13.17
9.79
17.91
7.06
growth rate -20.4% -25.7% 82.9% -60.6%
Acct.Payable 6.36
7.29
9.43
9.13
11.14
growth rate 14.6% 29.4% -3.2% 22.0%
Cur.Assets 133.06
126.56
140.69
163.05
174.70
growth rate -4.9% 11.2% 15.9% 7.1%
Total Assets 585.96
589.32
600.87
601.59
629.72
growth rate 0.6% 2.0% 0.1% 4.7%
Cash 31.29
61.35
86.58
18.75
10.64
growth rate 96.1% 41.1% -78.3% -43.3%
Inventory 1.75
3.84
4.03
1.92
7.63
growth rate 119.1% 5.0% -52.3% 296.7%
Cur.Liabilities 12.24
220.35
226.13
227.13
227.00
growth rate 1,700.2% 2.6% 0.4% -0.1%
Liabilities 221.36
224.88
230.47
230.73
230.95
growth rate 1.6% 2.5% 0.1% 0.1%
LT Debt 204.65
0.00
growth rate -100.0%
Equity 364.60
329.76
338.26
341.29
371.83
growth rate -9.6% 2.6% 0.9% 9.0%
Common Shares 0.02
0.03
0.02
0.02
growth rate 33.3% -25.0% 0.0%
Cash Flow Statement Mar '16 Jun '16 Sep '16 Dec '16 Mar '17
Capital Expenditures 0.24
0.78
0.76
0.07
0.09
growth rate 229.0% -2.7% -91.2% 29.9%
Cash Dividends
growth rate
Cash From OA 13.11
10.37
18.52
20.99
24.22
growth rate -20.9% 78.6% 13.3% 15.4%
Sale Purchase of Stock 0.51
1.47
2.63
-2.09
0.36
growth rate 187.5% 78.9% -100.0% 100.0%
FCF 12.88
9.59
17.76
20.93
24.14
growth rate -25.5% 85.2% 17.8% 15.3%
Income Statement Mar '16 Jun '16 Sep '16 Dec '16 Mar '17
Sales 29.65
19.52
21.62
38.19
29.27
growth rate -34.2% 10.7% 76.6% -23.4%
Op.Income 5.88
3.97
5.47
19.36
10.22
growth rate -32.5% 37.8% 254.1% -47.2%
IBT 9.57
-10.05
1.21
7.23
6.19
growth rate -100.0% 100.0% 496.9% -14.3%
Net Income 5.88
-6.17
1.05
-3.13
5.08
growth rate -100.0% 100.0% -100.0% 100.0%
EPS
growth rate
Gross Profit 28.69
18.80
20.62
35.29
28.93
growth rate -34.5% 9.7% 71.2% -18.0%
R&D 4.00
4.91
5.90
6.41
8.67
growth rate 22.7% 20.1% 8.7% 35.4%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

C (64.60)

YOY Growth Grade:

D (47.05)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE -748.75 -746.71 30.76
EPS / Growth 52.7% -0.15 35.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 35.0% 45.9% 60.6%
Future PE 0.01 20.51 50.65
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

Access denied

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE.